Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03497624 · ClinicalTrials.gov registry record
ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Completed
- Registry status
- 5
- Enrollment target
NCT03497624: Completed study, sponsored by Addario Lung Cancer Medical Institute.
NCT03497624 is a clinical trial that has completed, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03497624 has completed, sponsored by Addario Lung Cancer Medical Institute.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient derived PDX models will have no immediate benefit to the patient from whom the tumor specimen was obtained. Rather, these PDX models will be used to inform the study of ROS1-fusion driven cancers at large.
Primary Outcome
Successful generation of at least ten (10), but no more than twenty-four (24), ROS1-fusion PDX models with full characterization including whole exome sequencing (WES) and RNA sequencing. Models can be used as a resource for clinical and translational research to understand mechanisms of resistance and develop new therapies.
Interventions
- OTHER Biospecimens collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2020-09-04 |
What the finished NCT03497624 record still lists
NCT03497624 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biospecimens collection is the first listed.
NCT03497624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03497624 about?
NCT03497624 is a clinical study titled "ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors". Patient Derived Xenografts (PDXs) are models to study tumor growth, response to anti-cancer therapies, and resistance to anti-cancer therapies. The purpose of this study is to develop up to 24 PDX models for ROS1-fusion driven cancers to be used for research purposes only. That is, these patient der...
What is the current status of trial NCT03497624?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-04-23. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03497624?
The interventions under investigation include: Biospecimens collection (OTHER).
Who is sponsoring clinical trial NCT03497624?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI